Assistant Professor of Medicine (Hematology)
Smilow Classical Hematology
Classical Hematology, also known as “benign” hematology, is the area of non-cancer related blood disorders. Our hematologists provide a full spectrum of care to patients with non-malignant hematology disorders, and participate in research to advance treatment options for their patients. Educational and community outreach are also a priority to improve awareness and understanding of benign disorders.
The types of disorders that we care for are varied and include:
- Thrombosis: When blood clots form abnormally in a blood vessel, they can obstruct blood flow. We provide consultation services for patients who have developed thrombosis, including those with hereditary disorders of coagulation and acquired disorders (e.g. antiphospholipid antibody syndrome). These disorders are generally treated with anticoagulant drugs.
- Anemia: There are multiple causes of anemia, including nutrient deficiency (iron and vitamin B12), hereditary issues such as sickle cell disease and thalassemia, inflammation, immune conditions, and others.
- Bleeding and platelet disorders: Several disorders can result in excess bleeding. We care for patients with hemophilia through the Yale Hemophilia Treatment Center, von Willebrand disease, platelet disorders, and other rarer hereditary and acquired bleeding disorders. Clinical trials are underway utilizing new treatment modalities including gene therapy for these disorders. There are several different sub-types of von Willebrand disease (vWD), and accurately determining the type is important for treatment.
Other less common disorders cared for by our Classical Hematology team include vascular anomalies such as Hereditary Hemorrhagic Telangiectasia, paroxysmal nocturnal hemoglobinuria (PNH), porphyria, iron overload such as hereditary hemochromatosis, thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, among others. Please reach out if you have a concern or would like to review a patient’s diagnosis for follow-up care.
Classical Hematology Program
- Noffar Bar, MD, is an Assistant Professor of Medicine (Hematology) at Yale School of Medicine and completed her internship and residency at the Mount Sinai Hospital and her fellowship at Yale. She received her medical degree from the Sackler School of Medicine New York State/American Program of Tel Aviv University. Dr. Bar is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the International Myeloma Society. Dr. Bar’s research is focused on multiple myeloma and other plasma cell disorders. She specializes in all treatment modalities for myeloma including CAR T-cell therapy and stem cell transplant. She received grant support through the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma. Dr. Bar is dedicated to improving treatments for myeloma patients through innovative clinical trials. Additionally, Dr. Bar is a medical educator and a member of the Classical Hematology Disease team at Yale. She is interested in promoting high value care for hematology patients.
Professor of Internal Medicine (Hematology); Professor of Medicine, Hematology; Director, Classical Hematology Program; Medial Director, Hemophilia Treatment Center
Dr. Robert Bona, is the director of the classical (benign) hematology program and medical director of the Hemophilia Treatment Center at Yale. Originally from New York, he and his wife, Georg'Ann, are current residents of New Haven and long time residents of Connecticut where they have raised their three children. Prior to coming to Yale, he was a founding faculty member of the Frank H. Netter School of Medicine at Quinnipiac University. Prior to that he was Professor of Medicine at the University of Connecticut School of Medicine, having had early training there and at St. Francis Hospital in Hartford. At the UCONN School of Medicine, he served as the hematology oncology fellowship program director, chief of the division of hematology oncology and Hemophilia Treatment Center director. He has had a strong interest, throughout his career, in medical education and clinical hemostasis and thrombosis. He is a graduate of SUNY Upstate Medical College in Syracuse New York and is board certified in internal medicine, hematology and medical oncology. Learn more about Dr. Bona>>Assistant Professor of Medicine (Hematology)
Dr. Sabrina Browning received her medical degree from the University of Connecticut School of Medicine where she first confirmed her passion for caring for individuals with hematologic diseases. Her internship and residency were completed at Yale New Haven Hospital. After residency, Dr. Browning served as Amyloid Fellow at the internationally recognized Amyloidosis Center at Boston University School of Medicine and Boston Medical Center. In this position, she played a key role in the multidisciplinary care of and coordination for patients with immunoglobulin light chain (AL) amyloidosis and related diseases. She returned to Yale New Haven Hospital to complete her fellowship in Medical Oncology and Hematology. Upon joining as faculty in the Hematology section at Yale School of Medicine, Dr. Browning was the sole awardee of the Bernard Forget Scholarship for 2020-2021, which supports deserving individuals who are transitioning into an academic career in Hematology. Dr. Browning is a physician in the Smilow Multiple Myeloma and Gammopathies Programs and also sees patients in the Classical Hematology Clinic and she is incredibly passionate about the comprehensive management of patients with rare hematologic disorders including AL amyloidosis and hereditary hemorrhagic telangiectasia or HHT. Dr. Browning’s clinical and research interests include evaluating new treatments for multiple myeloma, AL amyloidosis, and other hematologic diseases and their impact on outcomes and quality of life for patients. With the support of the Frederick DeLuca Foundation and the DeLuca Center for Innovation in Hematology Research, she is also studying the association between metabolic syndrome, which can include obesity, high blood pressure, high cholesterol, and diabetes, and the development of monoclonal gammopathy and multiple myeloma with the aim to learn more about potential preventative strategies. Dr. Browning has a clinical and research interest in the management of issues such as bleeding and clotting in individuals with multiple myeloma and AL amyloidosis. Dr. Browning serves as the Principal Investigator on several clinical trials here at Yale for patients with multiple myeloma and AL amyloidosis and is interested in design of new clinical trials to further help her patients and others living with these diseases. Dr. Browning serves as the representative for the Yale Cancer Center on the Faculty Advisory Council for Yale School of Medicine. She is a member of the American Society of Hematology (ASH), the International Myeloma Society (IMS), and the International Society of Amyloidosis (ISA). As a member of the HHT center here at Yale she is also a registered physician with CureHHT. Dr. Browning is dedicated to providing patient-centered and compassionate care to individuals and their families through a team-based approach. She is also committed to teaching trainees at various levels of medical training.Associate Professor of Medicine (Hematology); Director, Hematology/Oncology Fellowship Program
Dr. Alfred Ian Lee is an Associate Professor of Medicine (Hematology) and Program Director for the hematology/oncology fellowship program. He received his MD/PhD from the Yale School of Medicine in 2004. Dr. Lee completed residency in internal medicine at Brigham & Women’s Hospital, where he served as Chief Medical Resident, followed by a fellowship in hematology/oncology at Dana-Farber Cancer Institute. His primary academic interests are classical hematology, thrombosis, and medical education. He has received such honors as the Charles W. Bohmfalk Prize for teaching in the basic sciences, the Leah M. Lowenstein Award for excellence in the promotion of humane and egalitarian medical education, and the David J. Lefell Prize for Clinical Excellence.Associate Professor of Internal Medicine (Hematology); Research Leader, Myeloma Program, Hematology
Dr. Neparidze obtained her medical degree from Aieti Medical School in Tbilisi, Georgia in 2000. She subsequently completed Postdoctoral Research Fellowships at Emory, Northwestern and Yale Universities, followed by Internal Medicine Residency and Hematology/Medical Oncology Fellowship at Yale University. She has served as an assistant professor at Yale University School of Medicine, Medical Oncology/Hematology since 2012. She specializes in multiple myeloma, monoclonal gammopathies, AL amyloidosis, Waldenstrom's macroglobulinemia and classical hematology. Dr. Neparidze is the research leader for the myeloma program, and her research focus is on monoclonal gammopathies, multiple myeloma, with specific interests in advanced imaging, tumor heterogeneity and mechanisms of tumor progression and resistance in myeloma, including advancing and developing novel therapies for multiple myeloma.Learn more about Dr. Neparidze>>Assistant Professor of Clinical Pediatrics (Hematology/Oncology); Pediatric Medical Director, Yale Hemophilia Treatment Center, Pediatrics
My clinical interests include caring for pediatric patients with bleeding and clotting disorders as well as those with hematologic malignancies (blood cancers). I also have a special interest in pediatric palliative care.
Learn more about Dr. Robert Bona and his role in the Classical Hematology Program and the multidisciplinary approach involved in caring for patients.